Zymeworks to Acquire Theravance Biopharma, Inc.
Zymeworks is set to bolster its pharmaceutical portfolio by acquiring Theravance Biopharma, adding YUPELRI®, a groundbreaking nebulized long-acting muscarinic antagonist for COPD maintenance treatment. The deal, priced at $17 per share, is structured with a non-recourse financing mechanism, minimizing Zymeworks’ capital risk while maximizing shareholder value. This acquisition is expected to enhance Zymeworks' market position and bring much-needed innovation to COPD treatment options, signifying a significant step in advancing respiratory care.
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.